Want to see ES:ORY full AI Analyst Report?
Top Page
Oryzon Genomics SA
(BME:ORY)
Select Model
Select Model
Rating:47Neutral
Price Target:
€2.50
▼(-12.59% Downside)
Action:Reiterated
Date:08/06/26
The score is primarily weighed down by weak financial performance—ongoing losses, volatile/zero revenue years, and sustained negative free cash flow—partly offset by a comparatively supportive balance sheet with modest leverage. Technical indicators are broadly neutral and do not provide a strong positive catalyst, while valuation metrics are constrained by loss-making status (negative P/E) and no dividend yield.
Positive Factors
Proprietary Epigenetics Focus
Oryzon’s proprietary epigenetic approach gives it a defined scientific platform aimed at oncology and CNS disorders with high unmet need. If clinical development succeeds, this focused technology base could support multiple therapies and create durable differentiation beyond a single candidate.
Negative Factors
Persistent Unprofitability
Oryzon has not yet demonstrated a profitable operating model, as recurring operating and net losses continue to exceed any gross profit generated. This keeps the company dependent on external capital or future commercialization success to support its long-term development strategy.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Epigenetics Focus
Oryzon’s proprietary epigenetic approach gives it a defined scientific platform aimed at oncology and CNS disorders with high unmet need. If clinical development succeeds, this focused technology base could support multiple therapies and create durable differentiation beyond a single candidate.
Read all positive factors
Oryzon Genomics SA (ORY) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€198.99M
Dividend YieldN/A
Average Volume (3M)155.99K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue GrowthN/A
EPS Growth53.50%
CountryES
Employees46
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding84,332,150
10 Day Avg. Volume127,864
30 Day Avg. Volume155,988
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)€9.00M
Oryzon Genomics SA Business Overview & Revenue Model
Company Description
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinica...
Oryzon Genomics SA Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
68
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.22M | 0.00 | 7.36M | 14.19M | 0.00 | 10.62M |
| Gross Profit | 3.98M | -133.91K | 7.06M | 13.95M | 15.23M | 9.87M |
| EBITDA | -6.55M | -6.29M | -4.43M | -4.41M | -5.33M | -6.88M |
| Net Income | -2.18M | -2.61M | -3.67M | -3.35M | -4.23M | -4.69M |
Balance Sheet | ||||||
| Total Assets | 141.70M | 144.52M | 108.72M | 106.90M | 103.70M | 95.38M |
| Cash, Cash Equivalents and Short-Term Investments | 22.12M | 28.37M | 5.62M | 12.26M | 21.32M | 28.72M |
| Total Debt | 7.10M | 11.94M | 16.21M | 13.69M | 17.44M | 17.66M |
| Total Liabilities | 23.41M | 26.68M | 21.67M | 25.13M | 31.13M | 24.12M |
| Stockholders Equity | 104.32M | 105.45M | 87.04M | 81.77M | 72.57M | 71.26M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.42M | -13.40M | -15.08M | -16.12M | -15.39M |
| Operating Cash Flow | 0.00 | -2.36M | -5.69M | -574.96K | -1.85M | -3.63M |
| Investing Cash Flow | 0.00 | -11.04M | -7.81M | -14.50M | -14.27M | -11.72M |
| Financing Cash Flow | 0.00 | 36.13M | 6.87M | 6.02M | 8.71M | 4.12M |
Oryzon Genomics SA Technical Analysis
Negative
2.86
Price Trends
2.71
Negative
2.84
Negative
2.90
Negative
Market Momentum
-0.07
Positive
34.42
Neutral
14.66
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ORY, the sentiment is Negative. The current price of 2.86 is above the 20-day moving average (MA) of 2.59, above the 50-day MA of 2.71, and below the 200-day MA of 2.90, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 34.42 is Neutral, neither overbought nor oversold. The STOCH value of 14.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:ORY.
Oryzon Genomics SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €1.20B | 20.69 | 23.64% | 1.48% | 15.52% | 34.76% | |
61 Neutral | €1.50B | 11.10 | 18.19% | 2.65% | 31.88% | -20.09% | |
52 Neutral | €212.43M | 30.46 | 3.14% | 0.75% | -0.42% | 4.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €198.99M | -77.82 | -2.23% | ― | ― | 53.50% |
* Healthcare Sector Average
ES:ORY
Oryzon Genomics SA
2.43
-1.11
-31.41%
ES:FAE
Faes Farma
4.83
0.46
10.59%
ES:RJF
LABORATORIO REIG JOFRE
2.58
-0.29
-10.01%
ES:PHM
Pharma Mar SA
67.50
-4.92
-6.79%
ES:IKM
1nKemia IUCT Group SA
0.31
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.